Our study demonstrate that SESN3 is significantly down-regulated in T-ALL patient samples and acts as a novel tumor-suppressor in T-ALL, which is in line with the fact that SESN3 suppresses the growth of BCR-ABL+leukemic cells [35]. Here, BCR is linked to neoplasm.